Anthrax Fusion Toxins with Improved Ability to Penetrate Cells
Available for licensing are novel conjugated or fusion proteins comprised of anthrax toxin lethal factor cytolethal distending toxin subunit B. Several human tumor cell lines have been found to be highly sensitive to these toxins with LD50 values in the pM range. In vivo studies in mice have revealed that these toxins selectively treat tumors and have very low systemic toxicity.
|Potential Commercial Applications:||Competitive Advantages:||
Stephen Leppla (NIAID)
Christopher Bachran (NIAID)
US Application No. 61/837,428
Patrick McCue , Ph.D.
NIH Office of Technology Transfer
OTT Reference No: E-120-2013/0